Q2 2025 Altimmune Inc Earnings Call Transcript
Key Points
- Pemvidutide achieved statistical significance in the primary endpoint of match resolution and across multiple objective measures of efficacy at 24 weeks of treatment.
- The company has a strong cash position with $183.1 million in cash and cash equivalents, which is a 40% increase over the start of the year.
- Pemvidutide demonstrated class-leading safety and tolerability without the need for dose titration, which is attractive to prescribers.
- Altimmune Inc (ALT) is advancing its NASH program and has initiated Phase 2 trials in AUD and ALD, addressing significant unmet needs.
- The appointment of Jerry Durso as Chairman of the Board brings valuable commercial and corporate development experience to the company.
- The fibrosis improvement in the impact trial did not reach statistical significance, although there was evidence of anti-fibrotic activity.
- The company faces uncertainties regarding FDA acceptance of non-invasive tests (NITs) for Phase 3 trial design.
- There is a potential risk of not achieving statistical significance in fibrosis endpoints without longer and larger trials.
- The net loss for the second quarter of 2025 was $22.1 million, indicating ongoing financial challenges.
- The company is still in the early stages of its AUD and ALD trials, with no immediate data readouts expected.
Good morning ladies and gentlemen and welcome to the Altimmune second-quarter 2025 financial results conference call. (Operator Instructions)
As a reminder, this call is being recorded. Let me introduce your host for todayâs conference call, Lee Roth, President of Burns McClellan Investor Relations Advisor to Altimune. Lee, you may begin.
Thanks, Olivia. Good morning everyone. Once again, thank you for joining us for the Altimmune second quarter 2025 financial results and Business Update conference call. On todayâs call youâll hear from Dr. Vipin Garg, our Chief Executive Officer; Dr. Scott Harris, our Chief Medical Officer; and Greg Weaver, our Chief Financial Officer; Dr. Scot Roberts, Our Chief Scientific Officer; and Ray Jordt, our Chief Business Officer will join us for the Q&A.
Our second-quarter 2025 financial results and corporate update press release was issued earlier this morning and it can be found on the Investor Relations section of the Altimmune website. Before we begin, Iâd like to remind
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
